Neurocrine Biosciences Inc. (NBIX)

91.45
1.80 1.90
NASDAQ : Health Technology
Prev Close 93.25
Open 93.85
Day Low/High 90.71 / 94.30
52 Wk Low/High 41.76 / 94.48
Volume 479.24K
Avg Volume 759.30K
Exchange NASDAQ
Shares Outstanding 89.90M
Market Cap 8.35B
EPS -1.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Neurocrine Biosciences To Present At The Bank Of America Merrill Lynch 2018 Healthcare Conference

Live Audio Webcast Will be on May 15, 2018

Neurocrine Biosciences Presents New Quality Of Life Data From RE-KINECT, The Largest Real-World Screening Study Of Possible Tardive Dyskinesia In Patients Treated With Antipsychotics

- Nearly 28 Percent of Patients Treated with Antipsychotics in the RE-KINECT Study Had Clinician-Confirmed Possible Tardive Dyskinesia

Neurocrine Biosciences To Present New Data From RE-KINECT, The Largest Real-World Screening Study Of Possible Tardive Dyskinesia Patients, At The 2018 American Psychiatric Association Annual Meeting

New Data Provide Insight Into the Real-World Impact of Potential Tardive Dyskinesia in Patients Treated With Antipsychotic Medicines

A Bullish Play on Neurocrine Biosciences

A Bullish Play on Neurocrine Biosciences

Analysts weren't shy to defend the company after Tuesday's earnings.

Neurocrine Biosciences Presents New Data Analyses At AAN Annual Meeting Demonstrating INGREZZA® Improved Tardive Dyskinesia Symptoms Across Body Regions

Additional Long-Term Data Show INGREZZA Sustained Improvement of Tardive Dyskinesia Symptoms Through 48 Weeks of Treatment and was Well-Tolerated

Neurocrine Biosciences Announces Conference Call And Webcast Of First Quarter 2018 Financial Results

Conference Call and Webcast Scheduled for Monday, April 30

Tuesday Investor Blog: Is the Bull Market in Stocks Being Ripped to Shreds?

Tuesday Investor Blog: Is the Bull Market in Stocks Being Ripped to Shreds?

Bring your A-game in these markets or go home. Just keeping it real. Here is what you need to know on Tuesday.

15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies

15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies

'Balance sheets are flush with cash and there is a need to grow for large health care companies,' Jefferies analysts wrote.

Watch These Biotechs and the FDA Calendar

Watch These Biotechs and the FDA Calendar

Here are a few key events I will be watching closely for in the months ahead on stocks I think are buys at current levels.

3 Key Biotech Catalysts on the FDA Calendar

3 Key Biotech Catalysts on the FDA Calendar

A roundup of biotech names with actions pending at the FDA in coming weeks.

Neurocrine Biosciences To Present At The Leerink Partners 7th Annual Global Healthcare Conference

Neurocrine Biosciences To Present At The Leerink Partners 7th Annual Global Healthcare Conference

Live Audio Webcast Will be on February 15, 2018

Neurocrine Biosciences Announces Conference Call And Webcast Of Fourth Quarter And Year-End 2017 Financial Results

Neurocrine Biosciences Announces Conference Call And Webcast Of Fourth Quarter And Year-End 2017 Financial Results

Conference Call and Webcast Scheduled for Tuesday, February 13

Neurocrine Biosciences Provides Preliminary Fourth Quarter And Full-Year 2017 Sales Results And 2018 Program Milestones

Neurocrine Biosciences Provides Preliminary Fourth Quarter And Full-Year 2017 Sales Results And 2018 Program Milestones

- Total Preliminary Revenue for the Fourth Quarter of 2017 was Approximately $94 Million and $161 Million for the Full-Year 2017

Neurocrine Biosciences To Present At The 36th Annual J.P. Morgan Healthcare Conference

Neurocrine Biosciences To Present At The 36th Annual J.P. Morgan Healthcare Conference

Live Audio Webcast Will be on January 8, 2018

Neurocrine Biosciences Presents Long-term Data Analyses From Open-label KINECT 4 Phase III Study Demonstrating INGREZZA® Improves Tardive Dyskinesia Symptoms

Neurocrine Biosciences Presents Long-term Data Analyses From Open-label KINECT 4 Phase III Study Demonstrating INGREZZA® Improves Tardive Dyskinesia Symptoms

- INGREZZA (valbenazine) Capsules Taken Once-daily Improved Tardive Dyskinesia Symptoms in Patients and was Generally Well Tolerated in 52-week Trial

Who Benefits From Tax Reform?

Who Benefits From Tax Reform?

Technology and biotech companies seem to be among the big winners.

Neurocrine Biosciences Soars on Third-Quarter Results -- Biotech Movers

Neurocrine Biosciences Soars on Third-Quarter Results -- Biotech Movers

The San Diego firm said net product sales of Ingrezza, a treatment for tardive dyskinesia, were $45.8 million during the quarter. The FDA approved Ingrezza in April.

10 Sectors That Will Profit Big-Time From Oil's Crash

10 Sectors That Will Profit Big-Time From Oil's Crash

Oil prices are tumbling down. Bad news for companies and petro states, but great news at the pump and for these ten industries...

Short Interest In Neurocrine Biosciences Increases 16%

The most recent short interest data has been released for the 06/15/2017 settlement date, which shows a 1,118,638 share increase in total short interest for Neurocrine Biosciences, Inc. , to 8,122,994, an increase of 15.97% since 05/31/2017.

Biotech Movers: Inovio, Neurocrine, Alnylam

Biotech Movers: Inovio, Neurocrine, Alnylam

Inovio Pharmaceuticals, Neurocrine Biosciences and Alnylam Pharmaceuticals were among the biotech movers in premarket trading on Wednesday.

Week in Review: Wall Street Sees Red as Geopolitical Issues Dominate, Earnings Begin

Week in Review: Wall Street Sees Red as Geopolitical Issues Dominate, Earnings Begin

Geopolitical concerns dominated market moves as banks kicked off earnings season.

U.S. Markets Close Lower as Wall Street Frets Over Global Turmoil

U.S. Markets Close Lower as Wall Street Frets Over Global Turmoil

Stocks closed lower Wednesday as markets continue to grapple with geopolitical uncertainty.

TheStreet Quant Rating: D+ (Sell)